Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy
Homayoun Zargar(University of British Columbia), Philippe E. Spiess(Moffitt Cancer Center), Siamak Daneshmand(Unknown), Peter C. Black(University of British Columbia), Jay B. Shah(The University of Texas MD Anderson Cancer Center), Trinity J. Bivalacqua(University of Pennsylvania), Wassim Kassouf(McGill University), Bas W. van Rhijn(University of Regensburg)
Cited by 80
Related Papers
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
|New England Journal of Medicine|2005|3.1k
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|798
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
|World Journal of Urology|2016|471